Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Nina V. Malkevich"'
Autor:
Boris Ionin, Ronald T. Aimes, Edward Bernton, Gabriel T. Meister, George Atiee, Robert J. Hopkins, Mario H. Skiadopoulos, Eric M. Vela, Nina V. Malkevich, Gary S. Nabors, Virginia Johnson
Publikováno v:
Antimicrobial agents and chemotherapy. 58(7)
Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis . Timely administration of antibiotics approved for the treatment of anthrax disease may prevent associated morbidity and mortality. However, any delay in
Autor:
Nina V. Malkevich, Mario H. Skiadopoulos, Gary S. Nabors, Boris Ionin, Kristin H. Clement, Ronald T. Aimes, Ajoy C. Chakrabarti, Subhendu Basu, Thomas L. Rudge
Development of anthrax countermeasures that may be used concomitantly in a postexposure setting requires an understanding of the interaction between these products. Anthrax immune globulin intravenous (AIGIV) is a candidate immunotherapeutic that con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e930ed6d734f18426fe6306aa3d9fe4c
https://europepmc.org/articles/PMC3811249/
https://europepmc.org/articles/PMC3811249/
Autor:
Cris Howard, Nancy F. Daczkowski, Gary S. Nabors, William Kramer, Daniel C. Sanford, Jason E. Comer, Nina V. Malkevich, Mohamed Al-Ibrahim, Ajoy C. Chakrabarti, Gabriel T. Meister, Robert J. Hopkins, Mario H. Skiadopoulos, Boris Ionin, Nutan Mytle, Kristopher E. Van Zandt, Subhendu Basu
Bacillus anthracis toxins can be neutralized by antibodies against protective antigen (PA), a component of anthrax toxins. Anthrivig (human anthrax immunoglobulin), also known as AIGIV, derived from plasma of humans immunized with BioThrax (anthrax v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ce9e951504878fe3cb3a74694991f92
https://europepmc.org/articles/PMC3811278/
https://europepmc.org/articles/PMC3811278/